SAN ANTONIO — The addition of inavolisib to palbociclib (Ibrance) plus fulvestrant (Faslodex) boosted progression-free survival (PFS) in patients with recurrent PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, according to the INAVO120 trial.
In patients who recurred within 12 months of adjuvant endocrine therapy, treatment with the investigational selective PI3Kα inhibitor demonstrated more than a doubling of median PFS from 7.3 to 15 months (stratified HR 0.43, P
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/meetingcoverage/sabcs/107777
